100 CAMPUS DRIVE, FLORHAM PARK, NJ
Director Departure - Stefan D. Loren Not Standing for Reelection
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences Enters Registered Direct Offering of 1,618,053 Shares
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Earnings Release
Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refract
Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload